PYC Therapeutics Limited · ASX:PYC
PYC Therapeutics — Shareholder Meeting (November 2026)
37 slides from PYC Therapeutics's shareholder meeting presentation, Nov 12, 2026
Slide 1: Annual General Meeting
rsonal use only Life-changing science Annual General Meeting 12 November 2026
Slide 2: Meeting opening
Meeting opening rsonal use only PYC THERAPEUTICS 2
Slide 3: Chair's address: Peter Coleman
Chair’s address: Peter Coleman rsonal use only PYC THERAPEUTICS 3
Slide 4: Financial Statements & auditor questions
Financial Statements & auditor questions rsonal use only PYC THERAPEUTICS 4
Slide 5: Formal Resolutions
Formal Resolutions rsonal use only PYC THERAPEUTICS 5
Slide 6: Proxy Summary
PROXY SUMMARY For Against Discretionary Totals Exclusions Abstain rsonal use only Votes Holders Votes Holders Votes Holders Votes Holders Votes Holders Votes Holders Resolution 1: Remuneration 307,558,364 86 42,208,095 14 68,495 7 349,834,954 102 381,000 1 99,258 5 Report 87.92% 84.31% 12.06% 13.73%
Slide 7: Proxy Summary (continued)
PROXY SUMMARY For Against Discretionary Totals Exclusions Abstain rsonal use only Votes Holders Votes Holders Votes Holders Votes Holders Votes Holders Votes Holders Resolution 6: Approval to issue 461,904,145 84 751,095 16 65,130 7 462,720,370 105 0 0 17,164 4 Performance Rights to Dr. Rohan Hockin
Slide 8: Resolution: Remuneration Report
Resolution 1 Remuneration Report rsonal use only ‘That the Remuneration Report for the year ended 30 June 2026 be adopted by the Company.’ a. 307,558,364 is to vote for the resolution 87.92% b. 42,208,095 is to vote against the resolution 12.06% c. 68,495 may vote at the proxy’s direction 0.02% d. 9
Slide 9: Re-election of Mr. Peter Coleman as a Director
Resolution 2 Re-election of Mr. Peter Coleman as a Director of the Company rsonal use only ‘That Mr. Peter Coleman, who retires in accordance with Rule 20.3 of the Constitution of the Company and Listing Rule 14.4 and, being eligible, offers himself for re-election, be re-elected as a Director.’ a.
Slide 10: Re-election of Professor Ian Constable AO as a Director
Resolution 3 Re-election of Professor Ian Constable AO as a Director rsonal use only ‘That Professor Ian Constable AO, who retires by rotation in accordance with Rule 20.6 of the Constitution and Listing Rule 14.4 and, being eligible, offers himself for re-election, be re-elected as a Director.’ a.
Slide 11: Approval to issue options to Dr. Rohan Hockings
Resolution 4 Approval to issue options to Dr. Rohan Hockings rsonal use only ‘That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 1,500,000 Options to the Executive Director & Chief Executive Officer, Dr. Rohan Hockings (or his no
Slide 12: Approval to issue Restricted Rights to Dr. Rohan Hockings
Resolution 5 Approval to issue Restricted Rights to Dr. Rohan Hockings rsonal use only ‘That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 289,855 Restricted Rights to the Executive Director & Chief Executive Officer, Dr. Rohan H
Slide 13: Approval to issue Performance Rights to Dr. Rohan Hockings
Resolution 6 Approval to issue Performance Rights to Dr. Rohan Hockings rsonal use only ‘That, for the purposes of Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 810,381 Performance Rights to the Executive Director & Chief Executive Officer, Dr. Rohan
Slide 14: Approval to issue options to Professor Ian Constable AO
Resolution 7 Approval to issue options to Professor Ian Constable AO rsonal use only ‘That, for the purposes of Listing Rule 10.11 and for all other purposes, approval is given for the Company to issue up to 1,000,000 Options to Non-Executive Director, Professor Ian Constable AO (or his nominee(s)),
Slide 15: Approval to grant rights to Professor Ian Constable AO
Resolution 8 Approval to grant rights to Professor Ian Constable AO rsonal use only ‘That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 42,373 Rights to Non-Executive Director, Professor Ian Constable AO (or his nominee(s)) u
Slide 16: Approval to grant rights to Peter Coleman
Resolution 9 Approval to grant rights to Peter Coleman rsonal use only ‘That, for the purposes of ASX Listing Rule 10.14 and for all other purposes, approval is given for the Company to issue up to 61,441 Rights to Non-Executive Director, Mr. Peter Coleman (or his nominee(s)) under the NED Plan, on
Slide 17: Renewal of proportional takeover approval provisions
Resolution 10 Renewal of proportional takeover approval provisions rsonal use only ‘That, for the purpose of section 648G of the Corporations Act and for all other purposes, the existing proportional takeover approval provisions in the form set out in Rule 38 of the Constitution be renewed for a per
Slide 18: Ratification of prior issue of shares
Resolution 11 Ratification of prior issue of shares rsonal use only “That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders approve and ratify the issue of 85,489,067 ordinary fully paid shares in the capital of the Company issued on 11 February 2026 at an issue price of
Slide 19: Poll reconciliation
Poll reconciliation rsonal use only PYC THERAPEUTICS 19
Slide 20: CEO update: Dr Rohan Hockings
CEO update: Dr Rohan Hockings rsonal use only PYC THERAPEUTICS 20
Slide 21: Life-changing science
rsonal use only Life-changing science AGM presentation November 2026
Slide 22: Disclaimer
Disclaimer The purpose of this presentation is to provide an update of the business of PYC Therapeutics forward looking statements contained in this presentation with caution. rsonal use only Limited (ASX:PYC) [‘PYC’]. These slides have been prepared as a presentation aid only and the This presentat
Slide 23: PYC's mission: life-changing RNA therapies
rsonal use only PYC’s mission is to create life-changing RNA therapies that address the root cause of diseases resulting from insufficient gene expression The Company’s work is dedicated to patients who currently have no treatment options available Sierra – living with Phelan- McDermid Syndrome1 PYC
Slide 24: Objectives and format
Objectives and format • Current state - Provide a progress update on all four of PYC’s pipeline programs rsonal use only • Immediate outlook - Frame the 24-month outlook for each program • Longer-term future - Illustrate how the clinical development milestones anticipated over the next 24-months wil
Slide 25: Pipeline of clinical-stage drug candidates in areas of major unmet need
PYC has created a pipeline of clinical-stage drug candidates in areas of major unmet need Program Pre-clinical Clinical rsonal use only Prevalence1 Phase 1/2 Registrational PYC-003 Polycystic Kidney Disease 1 in 1,000 PYC-002 Phelan-McDermid Syndrome 1 in 7,300 PYC-001 Autosomal Dominant Optic Atrop
Slide 26: Preparing to advance PKD drug candidate into registrational studies
PYC is preparing to advance its PKD drug candidate into registrational studies1 Proposed clinical development pathway for PYC-003 demonstrating both historical progress and future development plans1 rsonal use only Progress to date New Drug Application (NDA)3 Combined Phase 1a/1b Study2 Phase 2/3 St
Slide 27: Clinical validation of target engagement in CY27 to support kidney investment
Clinical validation of target engagement in CY27 will support additional investment in the kidney Longer-term implications Immediate (24-month) objectives rsonal use only • Clinical proof of mechanism and concept PYC-003 Polycystic Kidney Disease • P3 design finalisation and regulatory alignment on
Slide 28: Immediate objective in Phelan-McDermid Syndrome: advance into clinical trials
PYC’s immediate objective in Phelan-McDermid Syndrome is to advance its drug candidate into clinical trials1 rsonal use only Progress to date Pre-clinical studies GLP. PK and Toxicology Studies Clinical Trials IND In vitro Rat NHP NHP and Rat Human 1. Subject to the risks and uncertainties outlined
Slide 29: Next-generation PMS candidates to guide CNS expansion
Investment in next-generation versions of the existing PMS candidate will guide the Company’s expansion in the CNS Longer-term implications Immediate (24-month) objectives rsonal use only • Clinical proof of mechanism and concept PYC-003 Polycystic Kidney Disease • P3 design finalisation and regulat
Slide 30: Preparing ADOA drug candidate for registrational studies
PYC is preparing for progression of the first disease-modifying drug candidate in ADOA into registrational studies Progress to date rsonal use only Phase 1a SAD Study Phase 1/2 MAD Study1 Phase 2/3 Study NCT06461286 NCT06970106 Cohorts 60 mcg 60 mcg (Q12W) Objectives of Phase 1/2/3 trials of PYC-001
Slide 31: ADOA drug candidate potential in multiple blinding eye diseases
PYC’s ADOA drug candidate has potential in multiple blinding eye diseases1 Longer-term implications Immediate (24-month) objectives rsonal use only • Clinical proof of mechanism and concept PYC-003 Polycystic Kidney Disease • P3 design finalisation and regulatory alignment on path to NDA • Initiatio
Slide 32: Preparing RP11 drug candidate for registrational studies
PYC is preparing for the progression of the first disease- modifying drug candidate in RP11 into registrational studies1,2 rsonal use only Progress to date Open Label Phase 1a SAD Phase 1b MAD Study Phase 2/3 Study1 Extension Platypus (NCT05902962) Wallaby (NCT06455826) • Safety & Tolerability • Eff
Slide 33: Data and regulatory input to shape RP11 registrational path
Data from the ongoing P1/2 studies and regulatory input will shape the registrational path for the RP11 drug candidate Longer-term implications Immediate (24-month) objectives rsonal use only • Clinical proof of mechanism and concept PYC-003 Polycystic Kidney Disease • P3 design finalisation and reg
Slide 34: Q&A
rsonal use only Life-changing science Q&A November 2026
Slide 35: Shareholder questions
Shareholder questions rsonal use only PYC THERAPEUTICS 35
Slide 36: Announcement of results and close
Announcement of results and close rsonal use only PYC THERAPEUTICS 36
Slide 37: Thank you for your attendance
rsonal use only Thank you for your attendance
PYC Therapeutics — Shareholder Meeting (November 2026) on 6ix